Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + dexamethasone for previously treated AL amyloidosis
2011-001787-22Phase 2Active
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide and dexamethasone in light-chain amyloidosis, sponsored by IRCCS San Matteo Foundation. Primary endpoint: Hematologic response rate at 3 months. Started Jan 2012; status: active.
02
Drugs
pomalidomidedexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2011-001787-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001787-22.